

KIMBERLEY DRISCOLL

TERRENCE M. REIDY SECRETARY

The Commonwealth of Massachusetts Department of State Police

Forensic Services Division Crime Laboratory 124 Acton Street Maynard, MA 01754



JOHN D. PINKHAM **DEPUTY SUPERINTENDENT**

Telephone: (857) 377-3010 Facsimile: (857) 377-3035

SUPPLEMENTAL 1 POSTMORTEM TOXICOLOGY OUTSOURCING NOTIFICATION

Case Information:

Date Submitted: January 10, 2023

Notification Date: March 30, 2023

Laboratory No.: 23-00702

Date of Death: January 04, 2023

Medical Examiner Case No.: 23-186

Medical Examiner: Michele Matthews, MD

Decedent: Sayed Arif FAISAL

Specimens:

Item Number	Item Type	Miscellaneous Information
1-1-03	Iliac Blood	
1-1-03.1	Iliac Blood	Sent To Nmś

Specimen(s) were sent to National Medical Services (NMS) for testing.

ALL BIOLOGICAL SPECIMENS MAINTAINED AT THE MSPCL WILL BE DISPOSED OF 9 MONTHS AFTER DATE OF RECEIPT, UNLESS WRITTEN REQUEST FOR RETURN OF SAMPLES IS RECEIVED.

Nathaniel A. Almeida

Forensic Scientist II

This report was electronically signed using password protected software.

Page 1 of 1

Seq.#3



NMS Labs

200 Welsh Road, Horsham, PA 19044-2208 Phone: (215) 657-4900 Fax: (215) 657-2972 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Toxicology Report

Report Issued

To:

03/25/2023 15:07

20188Massachusetts State Police-Forensic Services

124 Acton St

Maynard, MA 01754

Patient Name

Not Provided

Patient ID

23-00702

Chain DOB

NMSCP241583

Sex

Not Given

Workorder

Not Given

23093989

Page 1 of 3

Positive Findings:

<u>Analyte</u>

Result

<u>Units</u>

Matrix Source

Caffeine Midazolam **Presump Pos**

mcg/mL

001 - Iliac Blood

49

ng/mL

001 - Iliac Blood

See Detailed Findings section for additional information

Testing Requested:

Test

Test Name

8052B

Postmortem, Expanded, Blood (Forensic)

Specimens Received:

ID Tube/Container

Volume/ Mass Collection Date/Time

Matrix Source

Labeled As

001 Blue Cap Plastic Tube

9 mL

Not Given

Iliac Blood

23-00702

All sample volumes/weights are approximations.

Specimens received on 03/10/2023.

NA



CONFIDENTIAL

Workorder Chain 23093989 NMSCP241583

Patient ID

23-00702

Page 2 of 3

Detailed Findings:

Analysis and Comments	Result	Units	Rpt. Limit	Specimen Source	Analysis By
Caffeine	Presump Pos	mcg/mL	0.20	001 - Iliac Blood	LC/TOF-MS
This test is an unconfirmed screen. Confirmation by a more definitive technique such as GC/MS is recommended.					
Midazolam	49	ng/mL	5.0	001 - Iliac Blood	LC-MS/MS

Other than the above findings, examination of the specimen(s) submitted did not reveal any positive findings of toxicological significance by procedures outlined in the accompanying Analysis Summary.

Reference Comments:

Midazolam (Versed®) - Iliac Blood:

Midazolam is a short acting benzodiazepine (a DEA Schedule IV controlled analyte) with sedative/hypnotic properties and is a strong central nervous system depressant. It is used for preoperative sedation, as a sedative hypnotic and as an agent for the induction of anesthesia. It has significant abuse potential. Effects noted following use may include sedation, somnolence (drowsiness or sleepiness), visual disturbances (diplopia or double vision), dysarthria (slurred speech), ataxia (shaky movements and unsteady gait), and intellectual impairment and coma may result. Oral doses of 10 mg given to 20 subjects produced average peak plasma concentrations for midazolam of 69 ng/mL in males and 53 ng/mL in females one hour post-dose. As a preoperative medication, intramuscular injection of midazolam at 0.13 mg/Kg body weight (9.1 mg/70 Kg body weight) produced peak plasma concentrations of 68 ng/mL. At high concentrations, confusion, impaired coordination, diminished reflexes, respiratory depression, apnea, hypotension, and coma may result.

Sample Comments:

001 Alternate Case ID: 1-1-03.1

001 Autopsy ID: 23-186

Unless alternate arrangements are made by you, the remainder of the submitted specimens will be discarded one (1) year from the date of this report; and generated data will be discarded five (5) years from the date the analyses were performed.

Workorder 23093989 was electronically signed on 03/25/2023 14:28 by:

Meaghan M. Ringel, M.S.F.S., D-ABFT-FT

Forensic Toxicologist

Meagher Engel

Analysis Summary and Reporting Limits:

All of the following tests were performed for this case. For each test, the compounds listed were included in the scope. The Reporting Limit listed for each compound represents the lowest concentration of the compound that will be reported as being positive. If the compound is listed as None Detected, it is not present above the Reporting Limit. Please refer to the Positive Findings section of the report for those compounds that were identified as being present.

Test 50012B - Benzodiazepines Confirmation, Blood - Iliac Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

<u>Analyte</u>	Rpt, Limit	<u>Analyte</u>	Rpt, Limit
7-Amino Clonazepam	5.0 ng/mL	Chlordiazepoxide	20 ng/mL
Alpha-Hydroxyalprazolam	5.0 ng/mL	Clobazam	20 ng/mL
Alprazolam	5.0 ng/mL	Clonazepam	2.0 ng/mL



CONFIDENTIAL

Workorder Chain 23093989 NMSCP241583

Patient ID 23-00702

Page 3 of 3

Analysis Summary and Reporting Limits:

<u>Analyte</u>	Rpt, Limit	<u>Analyte</u>	Rpt, Limit
Desalkylflurazepam	5.0 ng/mL	Lorazepam	5.0 ng/mL
Diazepam	20 ng/mL	Midazolam	5.0 ng/mL
Estazolam	5.0 ng/mL	Nordiazepam	20 ng/mL
Flurazepam	2.0 ng/mL	Oxazepam	20 ng/mL
Hydroxyethylflurazepam	5.0 ng/mL	Temazepam	20 ng/mL
Hydroxytriazolam	5.0 ng/mL	Triazolam	2.0 ng/mL

Test 8052B - Postmortem, Expanded, Blood (Forensic) - Iliac Blood

-Analysis by Enzyme-Linked Immunosorbent Assay (ELISA) for:

Analyte	Rpt. Limit	Analyte	Rpt. Limit
Barbiturates	0.040 mcg/mL	Gabapentin	5.0 mcg/mL
Cannabinoids	10 ng/mL	Salicylates	120 mcg/mL

-Analysis by Headspace Gas Chromatography (GC) for:

Analyte	Rpt. Limit	Analyte	Rpt. Limit
Acetone	5.0 mg/dL	Isopropanol	5.0 mg/dL
Ethanol	10 mg/dL	Methanol	10 mg/dL

-Analysis by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS) for: The following is a general list of analyte classes included in this screen. The detection of any specific analyte is concentration-dependent. Note, not all known analytes in each specified analyte class are included. Some specific analytes outside of these classes are also included. For a detailed list of all analytes and reporting limits, please contact NMS Labs. Amphetamines, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotics, Benzodiazepines, CNS Stimulants, Cocaine and Metabolites, Hallucinogens, Hypnosedatives, Muscle Relaxants, Non-Steroidal Anti-Inflammatory Agents, Opiates and Opioids.

NMS v.26.0